Propel Bio Management
Latest statistics and disclosures from Propel Bio Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are PAGP, ACHV, AKRO, MIST, APLT, and represent 63.15% of Propel Bio Management's stock portfolio.
- Added to shares of these 8 stocks: MIST (+$6.7M), CLDX, CMPS, NKTR, JSPR, DCTH, VRDN, Athira Pharma.
- Started 6 new stock positions in CLDX, CMPS, VRDN, Athira Pharma, NKTR, JSPR.
- Reduced shares in these 9 stocks: ACHV (-$7.5M), PHAT, CAPR, MATPF, ATHA, Eiger Biopharmaceuticals, TCRX, WTS - Achieve Life Sci, Chinook Therapeutics Cvr.
- Sold out of its positions in WTS - Achieve Life Sci, ATHA, CAPR, Chinook Therapeutics Cvr, Eiger Biopharmaceuticals, MATPF.
- Propel Bio Management was a net buyer of stock by $9.6M.
- Propel Bio Management has $100M in assets under management (AUM), dropping by 21.24%.
- Central Index Key (CIK): 0001969764
Tip: Access up to 7 years of quarterly data
Positions held by Propel Bio Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Propel Bio Management
Propel Bio Management holds 16 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Plains Gp Holdings Lp-cl Ltd Partnr Int A (PAGP) | 23.2 | $23M | 1.3M | 18.24 |
|
|
| Achieve Life Sciences (ACHV) | 11.9 | $12M | -38% | 3.8M | 3.15 |
|
| Akero Therapeutics (AKRO) | 10.9 | $11M | 229k | 47.48 |
|
|
| Milestone Pharmaceuticals (MIST) | 10.3 | $10M | +186% | 5.1M | 2.00 |
|
| Applied Therapeutics (APLT) | 6.8 | $6.8M | 11M | 0.60 |
|
|
| Phathom Pharmaceuticals (PHAT) | 6.5 | $6.5M | -40% | 553k | 11.77 |
|
| Abeona Therapeutics Com New (ABEO) | 5.1 | $5.1M | 974k | 5.28 |
|
|
| Delcath Systems Com New (DCTH) | 4.7 | $4.7M | +93% | 439k | 10.75 |
|
| Celldex Therapeutics Com New (CLDX) | 4.0 | $4.0M | NEW | 155k | 25.87 |
|
| Tscan Therapeutics (TCRX) | 3.5 | $3.5M | -7% | 1.9M | 1.82 |
|
| Compass Pathways Sponsored Ads (CMPS) | 2.9 | $2.9M | NEW | 510k | 5.73 |
|
| Nektar Therapeutics Com New (NKTR) | 2.8 | $2.8M | NEW | 49k | 56.90 |
|
| Jasper Therapeutics Com New (JSPR) | 2.5 | $2.4M | NEW | 1.0M | 2.38 |
|
| Zevra Therapeutics Com New (ZVRA) | 2.2 | $2.2M | 232k | 9.51 |
|
|
| Miragen Therapeutics (VRDN) | 1.9 | $1.9M | NEW | 90k | 21.58 |
|
| Athira Pharma | 0.6 | $618k | NEW | 149k | 4.14 |
|
Past Filings by Propel Bio Management
SEC 13F filings are viewable for Propel Bio Management going back to 2023
- Propel Bio Management 2025 Q3 filed Nov. 12, 2025
- Propel Bio Management 2025 Q2 filed Aug. 13, 2025
- Propel Bio Management 2025 Q1 filed May 15, 2025
- Propel Bio Management 2024 Q4 filed Feb. 14, 2025
- Propel Bio Management 2024 Q3 filed Nov. 13, 2024
- Propel Bio Management 2024 Q2 filed Aug. 12, 2024
- Propel Bio Management 2024 Q1 filed May 13, 2024
- Propel Bio Management 2023 Q4 filed Feb. 14, 2024